호르몬 피임약 시장 규모, 점유율, 성장 분석 : 제품별, 호르몬별, 연령별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Hormonal Contraceptive Market size was valued at USD 20.11 Billion in 2024 and is poised to grow from USD 20.95 Billion in 2025 to USD 29.12 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

The global market for hormonal contraceptives is experiencing significant expansion, driven by heightened awareness and acceptance of contraceptive options along with a rising demand for effective family planning solutions. While these methods excel at preventing pregnancy, they do not offer protection against sexually transmitted infections (STIs), necessitating additional protective measures. Consumers are increasingly opting for oral contraceptives, particularly combination pills, which dominate the market due to their efficacy and ease of use. However, progestin-only pills are emerging as a strong segment, anticipated to witness accelerated growth owing to their minimal side effects and compatibility for women unable to use oestrogen. This dynamic landscape reflects shifting preferences and the ongoing pursuit of reliable reproductive health options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptive Market Segments Analysis

Global Hormonal Contraceptive Market is segmented by Product, Hormones, End User, Age and region. Based on Product, the market is segmented into Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches. Based on Hormones, the market is segmented into Progestin Only Contraceptive and Combined Hormonal Contraceptive. Based on Age, the market is segmented into 15-24 Years, 25-34 Years, 35-44 Years and Above 44 Years. Based on End User, the market is segmented into Hospitals, Household and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is significantly driven by the heightened awareness and acceptance of contraception as a vital tool for family planning. As population growth continues, especially in developing regions, the demand for effective birth control solutions becomes increasingly pressing to help couples effectively manage family size and spacing. This burgeoning need has resulted in a notable rise in the utilization of hormonal contraceptives, which are recognized for their high efficacy in preventing unintended pregnancies. Additionally, their convenience and reversibility make hormonal contraceptives an attractive option for those seeking reliable family planning methods.

Restraints in the Global Hormonal Contraceptive Market

The global hormonal contraceptive market faces notable challenges stemming from social and cultural factors that hinder women's access to contraceptives. In various cultures and societies, contraception is often perceived unfavorably, with certain religious beliefs actively opposing its use. Additionally, limited awareness and education regarding contraceptive options further contribute to decreased demand in numerous regions. These issues significantly restrict market growth, particularly in areas where cultural norms and societal attitudes heavily influence decisions about contraceptive use. As a result, overcoming these barriers is crucial for enhancing accessibility and acceptance of hormonal contraceptives worldwide.

Market Trends of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is witnessing a notable shift towards long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) and subdermal implants, reflecting a growing consumer preference for effective, long-term birth control solutions. LARCs offer significant advantages, including high efficacy rates and minimal maintenance over extended periods, making them appealing to women seeking reliable and convenient contraceptive options. This trend is particularly prevalent among younger demographics, who are prioritizing not only effectiveness but also ease of use. Consequently, manufacturers are focusing on expanding LARC offerings, enhancing accessibility, and investing in educational initiatives to promote awareness and utilization of these options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hormonal Contraceptive Market Size by Product & CAGR (2026-2033)

• Market Overview
• Oral Contraceptive Pills
• Injectable Birth Control
• Emergency Contraceptive Pills
• Vaginal Rings
• Transdermal Patches

Global Hormonal Contraceptive Market Size by Hormones & CAGR (2026-2033)

• Market Overview
• Progestin Only Contraceptive
• Combined Hormonal Contraceptive

Global Hormonal Contraceptive Market Size by Age & CAGR (2026-2033)

• Market Overview
• 15-24 Years
• 25-34 Years
• 35-44 Years
• Above 44 Years

Global Hormonal Contraceptive Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Household
• Clinics

Global Hormonal Contraceptive Market Size & CAGR (2026-2033)

• North America (Product, Hormones, End User, Age)
  • US
  • Canada
• Europe (Product, Hormones, End User, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Hormones, End User, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Hormones, End User, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Hormones, End User, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afaxys, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pregna International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations